MAPT and Alzheimer disease: According to the report by the National Institute on Aging-Alzheimer’s Association (NIA-AA) in 2018 [1,3,4], the quantitative detection of AD biomarkers, including Aβ40 and Aβ42 peptides and phosphorylated and total tau proteins, in CSF was established as the diagnostic criteria for identifying probable AD patients.